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Abstract. 
 
By an expression cloning method using Fas-
transgenic Balb3T3 cells, we tried to obtain inhibitory 
genes against Fas-mediated apoptosis and identiﬁed 
proto-oncogene c-K-ras. Transient expression of K-Ras 
mutants revealed that oncogenic mutant K-Ras 
(RasV12) strongly inhibited, whereas dominant-inhibi-
tory mutant K-Ras (RasN17) enhanced, Fas-mediated 
apoptosis by inhibiting Fas-triggered activation of 
caspases without affecting an expression level of Fas. 
Among the target molecules of Ras, including Raf
(mitogen-activated protein kinase kinase kinase
[MAPKKK]), phosphatidylinositol 3 (PI-3) kinase, and 
Ral guanine nucleotide exchange factor (RalGDS), 
only the constitutively active form of Raf (Raf-CAAX) 
could inhibit Fas-mediated apoptosis. In addition,
the constitutively active form of MAPKK (SDSE-
MAPKK) suppressed Fas-mediated apoptosis, and 
MKP-1, a phosphatase speciﬁc for classical MAPK, 
canceled the protective activity of oncogenic K-Ras
(K-RasV12), Raf-CAAX, and SDSE-MAPKK. Fur-
thermore, physiological activation of Ras by basic ﬁbro-
blast growth factor (bFGF) protected Fas-transgenic 
Balb3T3 cells from Fas-mediated apoptosis. bFGF pro-
tection was also dependent on the activation of the 
MAPK pathway through Ras. All the results indicate 
that the activation of MAPK through Ras inhibits Fas-
mediated apoptosis in Balb3T3 cells, which may play a 
role in oncogenesis.
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Introduction
 
Apoptosis is a form of cell death fundamental to the em-
bryonic development and maintenance of homeostasis
(Rinkenberger and Korsmeyer, 1997). Disorders of the
process of apoptosis cause various pathologies, including
autoimmune diseases and neurodegenerative diseases.
Apoptosis is especially important to inhibit oncogenesis
because (a) tumor-suppressor genes can induce apoptosis
that is triggered by an abnormal progression of the cell cy-
cle promoted by cellular or viral oncogenes; and (b) de-
fects of proapoptotic genes frequently result in the tumori-
genesis (Williams, 1991; Yin et al., 1997).
Apoptosis is also induced by the stimulation of death re-
ceptors, members of the tumor necrosis factor receptor su-
perfamily (Nagata, 1997). These death receptors are char-
acterized by the presence of a death domain within their
cytoplasmic regions and can induce apoptosis triggered by
binding of their ligands. Fas (CD95/APO-1) is the best-
characterized death receptor, having been identified by
preparing agonistic anti-Fas mAb with cell-killing activity
(Yonehara et al., 1989; Itoh et al., 1991). Fas is involved in
the elimination of self-reactive lymphocytes and tumor
cells (Zornig et al., 1995; Peng et al., 1996; Maeda et al.,
1999). Stimulation of Fas with agonistic antibodies or Fas
ligand leads to the clustering of Fas. This enables both the
adapter molecule Fas-associated death domain (FADD)
 
1
 
/
MORT1 (Boldin et al., 1995; Chinnaiyan et al., 1995) and
the complex of caspase-8 (FADD-like interleukin-1
 
b
 
–con-
verting enzyme [FLICE]/MACH/MCH5) (Boldin et al.,
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 bFGF, basic FGF; EF1
 
a
 
, elongation fac-
tor 1
 
a
 
; FADD, Fas-associated death domain; FLICE, FADD-like inter-
leukin-1
 
b
 
–converting enzyme; FLIP, FLICE-inhibitory protein; GFP,
green fluorescence protein; IGF, insulin-like growth factor; K-RasV12,
oncogenic K-Ras; MAP , mitogen-activated protein; MAPK, MAP kinase;
MAPKK, MAPK kinase; MAPKKK, MAPKK kinase; MKP-1, MAPK
phosphatase 1; MST1, mammalian STE-20–like protein kinase; MST1-
KD, kinase-defective MST1; PE, phycoerythrin; PI-3, phosphatidylino-
sitol 3; PKB, protein kinase B; Raf-CAAX, constitutively active Raf;
RalGDS, Ral guanine nucleotide exchange factor; RT, reverse trancrip-
tion; SDSE-MAPKK, constitutively active MAPKK. 
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1996; Muzio et al., 1996; Srinivasula et al., 1996) and
FLICE-associated huge protein (FLASH) (Imai et al.,
1999) to be recruited to the cytoplasmic region of the
receptor, forming the death-inducing signaling complex
(DISC) (Kischkel et al., 1995; Imai et al., 1999). In DISC,
caspase-8 is proteolytically activated and then initiates ac-
tivation of the other caspases, which results in the induc-
tion of apoptosis (Medema et al., 1997).
Some types of apoptosis are known to be inhibited by
the activation of Akt/protein kinase B (PKB) or mitogen-
activated protein kinase (MAPK)/extracellular signal reg-
ulatory kinase (ERK). Activation of Akt/PKB was re-
ported to prevent the apoptosis induced by withdrawal of
survival factors such as insulin-like growth factor (IGF)-I
or NGF in neurons (Dudek et al., 1997; Philpott et al.,
1997), and interleukin-3 in hematopoietic cells (Songyang
et al., 1997). Akt/PKB also inhibits the apoptosis induced
by activation of Myc in the absence of serum in fibroblasts
(Kauffmann-Zeh et al., 1997; Kennedy et al., 1997) and by
detachment of epithelial cells from the extracellular ma-
trix (Khwaja et al., 1997). MAPK was reported to inhibit
the apoptosis induced by withdrawal of NGF in neurons
(Xia et al., 1995) and by the expression of Hid in 
 
Dro-
sophila
 
 (Bergmann et al., 1998; Kurada and White, 1998).
In the case of the death receptors, Fas-mediated apoptosis
was reported to be inhibited by a cellular gene, c–FLICE-
inhibitory protein (FLIP) (Irmler et al., 1997), the expres-
sion of which was suggested to be upregulated by activated
MAPKK in T lymphocytes (Yeh et al., 1998). However, it
was also reported that activated T cells in early phase are
resistant to Fas stimulation independently of c-FLIP.
The key regulator upstream of both Akt/PKB and
MAPK is a small G protein Ras, known as an oncogene
product. GTP-bound active Ras recruits its effector mole-
cules, including Raf and phosphatidylinositol 3 (PI-3) ki-
nase, under the plasma membrane and then activates the
Raf/MAPK pathway and the PI-3 kinase/Akt pathway, re-
spectively. Here, we report that c-K-Ras suppresses Fas-
mediated apoptosis, and oncogenic Ras strongly protects
cells against Fas-mediated apoptosis through the activa-
tion of the MAPK pathway in Fas-transgenic Balb3T3
cells. In addition, we found that basic FGF (bFGF) but not
EGF confers resistance on the fibroblasts against Fas-medi-
ated apoptosis. This protective ability of bFGF was also
shown to be mediated by the activation of the Ras/MAPK
pathway. Although it was recently reported that oncogenic
Ras downregulates the expression of Fas through activa-
tion of the PI-3 kinase/Akt pathway (Peli et al., 1999), the
MAPK pathway inhibited Fas-mediated apoptosis without
affecting the expression level of Fas. Our results indicate
that the activation of MAPK inhibits Fas-triggered apop-
totic signaling in fibroblasts, which may play a role in on-
cogenesis.
 
Materials and Methods
 
Cell Lines
 
Mouse embryonic fibroblast Balb3T3 cells were kindly provided by K.
Nagata (Kyoto University, Kyoto, Japan). The cells were maintained in
DME supplemented with 10% FBS and 100 
 
m
 
g/ml kanamycin at 37
 
8
 
C in
5% CO
 
2
 
. Balb3T3 cells were transfected with the expression vector of
mouse Fas driven by human 
 
b
 
-actin promoter (Gunning et al., 1987), to-
 
gether with hygromycin B phosphotransferase gene inserted into the
BamHI/HindIII sites of pRc/CMV (Invitrogen). The transfected cells
were selected in DME with 10% FBS containing 200 
 
m
 
g/ml of hygromycin
B (Sigma Chemical Co.). Stably Fas-expressing Balb3T3, designated FH2,
was cloned based on the high-level expression of Fas analyzed by flow cy-
tometry after the staining with FITC-conjugated anti-Fas antibody RMF-6
(Nishimura et al., 1995), or phycoerythrin (PE)-conjugated anti-Fas anti-
body Jo-2 (PharMingen).
 
cDNA Library and Plasmid Constructs
 
cDNA was prepared by using time saver cDNA synthesis kit (Amersham
Pharmacia Biotech) from polyA
 
1
 
 RNA of Balb3T3 cells purified by oligo-dT
column (Amersham Pharmacia Biotech), and then subcloned into
pME18S expression vector (Sakamaki et al., 1992). Various mutants of
mouse Ras, K-RasV12, K-RasN17, K-RasS35, K-RasG37, and K-RasC40
(Kauffmann-Zeh et al., 1997), were prepared from c-K-Ras by using
Quick-Change site-directed mutagenesis kit (Stratagene). pJ7
 
V
 
-lacZ
(Morgenstern and Land, 1990) was used for the expression of 
 
b
 
-galactosi-
dase. Flag-tagged mammalian STE-20–like protein kinase (MST1) (Lee
et al., 1998) was mutagenized to be kinase-defective (MST1-KD) by re-
placement of lysine 59 with arginine (K59R). The proper construction of
all the mutants was confirmed by DNA sequencing. cDNAs encoding con-
stitutively active Raf (Raf-CAAX), 
 
D
 
p85, Akt, constitutively active Akt
(HA-m
 
D
 
4-129 Akt), and RalN28 were kind gifts from J.F. Hancock (Uni-
versity of Queensland Medical School, Brisbane, Australia), W. Ogawa
(Kobe University, Kobe, Japan), U. Kikkawa (Kobe University), R. Roth
(Stanford University, Stanford, CA), and L.A. Feig (Tufts University,
Medford, MA), respectively. cDNAs for constitutively active MAPKK
(SDSE-MAPKK) were provided by E. Nishida (Kyoto University), and
an expression vector for green fluorescence protein (GFP) was from K.
Umesono (Kyoto University).
 
Antibodies and Reagents
 
Agonistic anti–mouse Fas mAb RK-8 (Nishimura et al., 1995) was pro-
vided by Medical and Biological Laboratories (Nagoya, Japan). mAbs
against Ras (clone 18) and phospho-p42/44 MAPK (E10) were purchased
from Transduction Laboratories and New England Biolabs, respectively.
Polyclonal antibody against phospho-Akt was purchased from New En-
gland Biolabs. EGF purified from mouse submaxillary glands was from
Sigma Chemical Co. Recombinant human IGF-I and recombinant human
bFGF were from GIBCO BRL. Fluorescent substrates acetyl-Asp-Glu-
Val-Asp-
 
a
 
-(4-methyl-coumaryl-7-amide) (Ac-DEVD-MCA) and acetyl-
Ile-Glu-Thy-Asp-
 
a
 
-(4-methyl-coumaryl-7-amide) (Ac-IETD-MCA) for
caspase-3/7 and caspase-8/6, respectively, were purchased from Peptide
Institute. For staining 
 
b
 
-galactosidase–positive cells, 5-bromo-4-chloro-
3-indolyl-b-
 
D
 
-(
 
2
 
)-galactopyranoside (X-Gal) was purchased from Wako.
 
Expression Cloning
 
Subconfluent FH2 cells in five 10-cm dishes were transfected with
pME18S encoding the cDNA library described above by the calcium-
phosphate method (Sambrook et al., 1989). In brief, the cells were incu-
bated first in a culture medium containing 10% FBS with calcium-phos-
phate–DNA complex for 24 h, and then in fresh medium with 10% FBS
for another 24 h. After the incubation, cells were stimulated with 0.1–1.0
 
m
 
g/ml RK-8 for 4–6 h. Apoptotic cells were removed by washing with PBS
three times. The surviving cells that adhered to the dishes were collected
and episomal plasmids in the collected cells were recovered according to
the method described by Itoh et al. (1991). The recovered plasmids were
amplified in ElectroMAX DH10B cells (GIBCO BRL) and transfected
into FH2 cells. This cycle was repeated six times with the amplified plas-
mids obtained in the previous cycle.
 
Transient Transfection of Expression Vectors
 
For transient transfection, FH2 cells were seeded at 1 
 
3
 
 10
 
5
 
 cells per well
in 6-well plates. Cells were cultured for 1 d and then transfected with vari-
ous expression vectors (0.4 
 
m
 
g/each vector) by using Lipofectamine plus
(GIBCO BRL) according to the manufacturer’s protocol.
 
Assay of Fas-mediated Apoptosis in the
Transfected Cells
 
FH2 cells transfected with expression vectors (0.4 
 
m
 
g/each vector) and 0.4 
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m
 
g pJ7
 
V
 
-lacZ were cultured for 2 d and then transferred to 24-well plates
at 2 
 
3
 
 10
 
4
 
 cells per well. After cultivation for 12–16 h, cells were stimu-
lated with 200 ng/ml RK-8 for 0, 4, or 8 h, and fixed with PBS containing
2% formaldehyde and 0.2% glutaraldehyde for 5 min. After the removal
of apoptotic cells by washing with PBS, attached cells were stained with
PBS containing 1 mg/ml X-Gal, 0.02% NP-40, 5 mM K-ferricyanide, 5 mM
K-ferrocyanide, and 2 mM MgCl
 
2
 
 for 1 h at 37
 
8
 
C. The total number of
 
b
 
-galactosidase–positive cells per well was counted for each independent
transfection (
 
n
 
 
 
5 
 
3) under a microscope. Cell viability was represented by
the percentage of the number of 
 
b
 
-galactosidase–positive cells after treat-
ment with anti-Fas mAb against that before the treatment with anti-
Fas mAb.
 
In Vivo Analysis of Caspase-3 Activation
 
Cells were transfected with various expression vectors together with an
expression vector of Flag-tagged MST1-KD as a substrate for caspase-3.
2 d later, cells were stimulated with 0.2 
 
m
 
g/ml RK-8 and lysed in 50 mM
Tris-HCl, pH 7.5, containing 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 40 mM Na
 
2
 
P
 
2
 
O
 
7
 
, 50 mM NaF, 5 mM MgCl
 
2
 
, 100 
 
m
 
M
Na
 
3
 
VO
 
4
 
, 10 mM EDTA, and protease inhibitor cocktail (Sigma Chemical
Co.) at 4
 
8
 
C. For Western blotting, cell lysates were separated by 10%
SDS-PAGE and transferred to PVDF membrane (Millipore). The mem-
brane was blocked with 5% skim milk in PBST (PBS 
 
1
 
 0.05% Tween 20)
for at least 1 h, and then incubated with anti-Flag antibody M2 (Kodak)
for detection of intact and cleaved MST1-KD.
 
Cytotoxic Assay by Staining with Amido Black
 
FH2 cells (1 
 
3
 
 10
 
5
 
 cells/well) in 96-well plates were treated with anti-Fas
mAb RK-8 and stained with 0.05% amido black in 9% CH
 
3
 
COOH with
0.1 M CH
 
3
 
COONa for 30–60 min at room temperature. Cells were washed
with water, dried, and dissolved in 100 
 
m
 
l/well of 25 mM NaOH. Cell den-
sity was determined by measuring optical absorbance at 560 nm with a mi-
croplate reader (Molecular Devices).
 
Quantification of FLIP mRNA by Reverse 
Transcription PCR
 
One step reverse trancription (RT)-PCR with 2 
 
m
 
g total RNA was carried
out by using ready-to-go RT-PCR beads (Amersham Pharmacia Biotech)
supplemented with extra 1.25 U Pfu turbo (Stratagene). Primers used for
mouse cellular FLIP and elongation factor 1
 
a 
 
(EF1
 
a
 
)
 
 
 
were as follows:
mouse FLIP
 
L
 
, 5
 
9
 
-GAG CCA AGA TTT GTG GAA TAC CG-3
 
9
 
; mouse
FLIP
 
L
 
, 5
 
9
 
-TCT TCC AAC TGG CTA CCT AAC GAC T-3
 
9
 
; mouse
EF1
 
a
 
, 5
 
9
 
-TCC TAC CAC CAA CTC GTC CAA C-3
 
9
 
; and mouse EF1
 
a
 
,
5
 
9
 
-CAG CTT CTT ACC AGA ACG ACG ATC-3
 
9
 
.
 
Results
 
Cloning of c-K-Ras as a Gene Inhibiting
Fas-mediated Apoptosis
 
To search for inhibitory genes against Fas-mediated apop-
tosis, we prepared the cells sensitive to the stimulation of
Fas from Balb3T3 cells by transfecting an expression vec-
tor of mouse Fas under the control of human 
 
b
 
-actin pro-
moter. FH2 was sensitive to the stimulation of Fas. By us-
ing FH2 cells, we carried out expression cloning to obtain
cDNA that confers resistance to Fas-mediated apoptosis
in FH2 cells as described in Materials and Methods, and fi-
nally obtained c-K-Ras. To confirm the protective activity
of c-K-Ras, we cotransfected expression vectors encoding
c-K-Ras and 
 
b
 
-galactosidase, and quantified 
 
b
 
-galactosi-
dase–positive cells after stimulation of Fas (Fig. 1). Treat-
ment with agonistic anti-Fas mAb RK-8 dose-dependently
induced apoptosis in FH2 cells, and transient expression of
c-K-Ras suppressed this apoptosis (Fig. 1). We then ob-
served the morphologies of cells that were transfected
with an empty vector or an expression vector of c-K-Ras,
and treated with or without anti-Fas mAb for 4 h (Fig. 2,
A, B, E, and F). Control cells treated with anti-Fas mAb
showed an apoptotic morphology with a rounded form
and were detached from the culture dish (Fig. 2 E). In con-
trast, a significant number of the c-K-Ras–transfected cells
kept an extended morphology even after the stimulation
of Fas (Fig. 2 F). These results indicate that the overex-
pression of c-K-Ras decreases the sensitivity of fibroblasts
to Fas-mediated apoptosis.
 
Activated K-Ras Inhibits Fas-mediated Apoptosis
 
To analyze whether the inhibitory effect of c-K-Ras on
Fas-mediated apoptosis is reflected by the effects of active
(GTP-bound) or inactive (guanosine diphosphate–bound)
Ras, FH2 cells were transfected with an expression vector
of Ras mutant together with that of 
 
b
 
-galactosidase, con-
stitutively active Ras (K-RasV12), or dominant-inhibitory
Ras (K-RasN17). We counted the 
 
b
 
-galactosidase–posi-
tive cells transfected with K-RasV12 or K-RasN17 before
and after the treatment with anti-Fas mAb (Fig. 3 A)
and found that K-RasV12 strongly inhibited, whereas
K-RasN17 enhanced, Fas-mediated apoptosis. Fig. 2 G
shows that most of the cells transfected with K-RasV12
displayed an intact morphology after 4 h of stimulation
with anti-Fas mAb. In contrast, almost all the cells trans-
fected with K-RasN17 were completely detached from the
culture dish (Fig. 2 H). These results show that Fas-medi-
ated apoptosis is suppressed by activated K-Ras and en-
hanced by dominant-inhibitory K-Ras in FH2 cells.
 
Activated K-Ras Inhibits Activation of Caspases
 
Caspases play a central role in apoptosis by cleaving intra-
cellular proteins, including DNA fragmentation factor
(DFF) 45/Inhibitor of caspase-activated DNase (ICAD),
poly (ADP-ribose) polymerase (PARP), and protein ki-
Figure 1. c-K-Ras inhibits Fas-mediated apoptosis in FH2 cells.
FH2 cells were transiently transfected with an empty vector
(Control) or an expression vector of c-K-Ras together with pJ7V-
LacZ. Cells were treated with indicated concentrations of agonis-
tic anti-Fas mAb RK-8 for 8 h. The percentages of viable cells af-
ter Fas-stimulation were determined as described in Materials
and Methods. 
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nase MST (Lee et al., 1998). MST was directly cleaved
by caspase-3 both in vitro and in vivo (Lee, K.K., and
S. Yonehara, unpublished data). To investigate whether
K-RasV12 inhibits Fas-mediated apoptosis upstream or
downstream of caspase activation, we cotransfected
K-RasV12 with MST1-KD tagged with Flag as a substrate
for activated caspase-3, and analyzed the cleavage of
MST1-KD by caspase-3 after stimulation with anti-Fas
mAb by Western blotting. In control cells, MST1-KD began
to be cleaved after 1 h of stimulation and was almost com-
pletely cleaved within 4 h (Fig. 3 C). In the cells cotrans-
fected with K-RasV12, we could not observe cleaved
MST1-KD after 1 h of stimulation. In addition, most of the
MST1-KD remained full-length even after 4 h of stimula-
tion (Fig. 3 C), suggesting no activation of caspase-3. These
results indicate that K-RasV12 inhibits Fas-triggered apop-
totic signaling at a point upstream of caspase-3.
 
Activation of the MAPK Pathway Inhibits
Fas-mediated Apoptosis
 
GTP-bound active Ras was reported to transduce various
signals by activating multiple intracellular target mole-
cules, including Raf, PI-3 kinase, and Ral guanine nucle-
otide exchange factor (RalGDS) (Downward, 1998). To
investigate which target molecule of Ras is involved in
the protection against Fas-mediated apoptosis, we ana-
lyzed the effects of three partial loss-of-function mutants
derived from K-RasV12, K-RasS35, K-RasG37, and
K-RasC40, which were reported to activate only Raf, Ral-
GDS, and PI-3 kinase, respectively (Kauffmann-Zeh et al.,
1997). Fig. 3 A shows that K-RasS35 and K-RasG37 could
inhibit Fas-mediated apoptosis but that their protective
activities were significantly lower than that of K-RasV12.
K-RasC40 did not show significant suppressing activity
against Fas-mediated apoptosis in FH2 cells (Fig. 3 A), al-
though the expression was confirmed (Fig. 3 B). These re-
sults suggest that the protective activity of K-Ras against
Fas-mediated apoptosis depends on the activation of Raf
and/or RalGDS.
Raf is an activator of MAPKK, which is an activator of
MAPK. To confirm whether the activation of the MAPK
pathway is involved in the inhibition of Fas-mediated
apoptosis, FH2 cells were transfected with Raf-CAAX
(Stokoe et al., 1994) or SDSE-MAPKK (Fukuda et al.,
1997). Both Raf-CAAX and SDSE-MAPKK protected
FH2 cells against Fas-mediated apoptosis (Fig. 4 A) and
inhibited caspase-dependent cleavage of MST1-KD (Fig. 4
B). To further confirm the activation of MAPK to be es-
sential for Ras-dependent protection against Fas-medi-
ated apoptosis, we examined the effect of MKP-1, a phos-
phatase specific for activated MAPK, on the protective
activity of K-RasV12, Raf-CAAX, or SDSE-MAPKK in
FH2 cells. MKP-1, the expression of which was confirmed
by Western blotting (Fig. 4 C), completely canceled the
protective activity of K-RasV12, Raf-CAAX, and SDSE-
MAPKK against Fas-mediated apoptosis (Fig. 4 A) and
caspase-dependent cleavage of MST1-KD (Fig. 4 B).
Then we examined whether the RalGDS pathway is in-
volved in Ras-dependent protection, and dominant-inhibi-
tory mutant of Ral, RalN28, transfected with K-RasV12
into FH2 cells could not cancel Ras-dependent protection
Figure 2. Oncogenic K-Ras inhibits morphological changes in
Fas-mediated apoptosis. FH2 cells were transiently transfected
with an empty vector (Control), an expression vector of c-K-Ras,
constitutively active Ras (K-RasV12), or dominant-inhibitory
Ras (K-RasN17) together with pJ7V-LacZ and stained with
X-Gal before (A–D) or after (E–J) the stimulation with 200 ng/ml
anti-Fas mAb RK-8 for 4 (E–H) or 8 h (I and J). (A and E) Cells
were transfected with a control vector. After a 4-h stimulation of
Fas, almost all cells were detached from culture dishes. (B and F)
Cells were transfected with an expression vector of c-K-Ras.
About 40% of the c-K-Ras–transfected cells survived even after
a 4-h stimulation of Fas (F). (C, G, I, and J) Cells were trans-
fected with an expression vector of K-RasV12. Most of the cells
survived after 4 h of stimulation (G). Even after 8 h of stimula-
tion, many of the K-RasV12–transfected cells survived (I) and
developed filamentous structure (J). (D and H) Cells were trans-
fected with an expression vector of K-RasN17. All the cells stim-
ulated with 200 ng/ml RK-8 for 4 h were detached from culture
dishes (H). 
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against Fas-mediated apoptosis (data not shown). Re-
cently, H-Ras–dependent activation of PI-3 kinase, which
is an activator of Akt/PKB, was reported to prevent Fas-
mediated apoptosis by downregulating the expression
level of Fas (Peli et al., 1999). To test the effect of PI-3 ki-
nase activated by Ras on Fas-mediated apoptosis in FH2
cells, we transfected a mutant of PI-3 kinase subunit 
 
D
 
p85
(Sakaue et al., 1995), which was reported to dominantly in-
hibit Ras-dependent activation of PI-3 kinase (Rodriguez-
Viciana et al., 1997). Overexpression of 
 
D
 
p85, which was
confirmed by Western blotting (Fig. 4 D), did not prevent
the protective effect of K-RasV12 against Fas-mediated
apoptosis in FH2 cells, although the inhibitory effect of
 
D
 
p85 on phosphorylation of Akt/PKB by K-RasV12 was
confirmed (Fig. 4 D). Moreover, overexpression of consti-
tutively active Akt/PKB (Kohn et al., 1996) also did not
suppress Fas-mediated apoptosis (Fig. 4, A and E). All the
results indicate that the MAPK pathway but not the Akt/
PKB pathway plays an important role on K-Ras–depen-
dent protection against Fas-mediated apoptosis in FH2
cells.
To analyze whether K-RasV12, Raf-CAAX, and SDSE-
MAPKK regulate Fas-expression in FH2 cells that express
exogenous Fas under the control of human 
 
b
 
-actin pro-
moter, we analyzed the expression levels of Fas by flow
cytometry on the cells that were cotransfected with
K-RasV12, Raf-CAAX, or SDSE-MAPKK together with
GFP expression vector. Control cells highly expressed Fas
(Fig. 5 A), and the expression levels of Fas on GFP-inten-
sive cells were as high as those on GFP-negative cells (Fig.
5 B). These results indicate that K-RasV12, Raf-CAAX,
and SDSE-MAPKK do not influence the Fas-expression
enforced by human 
 
b
 
-actin promoter in FH2 cells, because
GFP-intensive cells were considered to highly express
K-RasV12, Raf-CAAX, or SDSE-MAPKK. In addition,
the expression level of endogenous Fas in parental Balb3T3
cells was also unaffected by overexpressed K-RasV12,
Raf-CAAX, or SDSE-MAPKK (Fig. 5 C). These results
 
indicate that activation of the MAPK pathway by K-Ras
does not regulate the expression level of Fas.
 
Pretreatment with bFGF Inhibits
Fas-mediated Apoptosis
 
To examine whether physiological activation of MAPK is
sufficient to inhibit Fas-mediated apoptosis, FH2 cells
were pretreated with several growth factors, including
EGF, IGF, and bFGF, which are known to activate
MAPK, and then stimulated with anti-Fas mAb. After
pretreatment with bFGF for 
 
.
 
12 h, FH2 cells showed a re-
sistant phenotype to Fas-mediated apoptosis, although the
cells pretreated with either EGF or IGF were as sensitive
as nontreated cells (Fig. 6 A). Then we compared the ki-
netics of the phosphorylation of MAPK after the treat-
ment with EGF, IGF, and bFGF. bFGF treatment induced
a strong and sustained phosphorylation of MAPK (Fig. 6
B). EGF treatment induced a relatively transient phos-
phorylation of MAPK (Fig. 6 B). These results suggest
that strong and constitutive activation of MAPK is neces-
sary to inhibit Fas-mediated apoptosis.
We then investigated Fas-triggered activation of cas-
pases in FH2 cells pretreated with or without bFGF
by using fluorescence tetrapeptides, IETD-MCA and
DEVD-MCA, as specific substrates for caspase-8/6 and
caspase-3/7, respectively. Protease activity of caspases
specific for both IETD and DEVD in control cells in-
creased markedly after a 2-h stimulation of Fas (Fig. 6, C
and D). However, in bFGF-treated cells, the protease ac-
tivity for IETD was completely suppressed even after a
4-h stimulation of Fas (Fig. 6 C). The protease activity for
DEVD was also distinctly suppressed by the pretreat-
ment with bFGF (Fig. 6 D), although it slightly increased
from 3 h after the stimulation of Fas. These results show
that bFGF suppressed Fas-triggered apoptotic signaling
at a point upstream of caspases the same as oncogenic
K-Ras.
Figure 3. Oncogenic K-Ras prevents, and domi-
nant-inhibitory K-Ras enhances, Fas-mediated
apoptosis. (A) FH2 cells were transiently trans-
fected with an empty vector (control) or an
expression vector of K-RasV12, K-RasN17,
K-RasS35, K-RasG37, or K-RasC40 together
with pJ7V-LacZ. K-RasS35, K-RasG37, and
K-RasC40 possess RasV12 background. The per-
centages of viable cells after 4 h of treatment
with 200 ng/ml agonistic anti-Fas mAb RK-8
were determined as described in Materials and
Methods. B, Transient expression of Ras mutants
was examined by Western blotting with anti-Ras
antibody. C, FH2 cells were co-transfected with
an empty vector (control) or an expression vec-
tor of K-RasV12 with that of MST1-KD tagged
with Flag as a substrate of caspase-3 to monitor
the Fas-triggered activation of caspases. After
stimulation of Fas for the indicated times, intact
and cleaved Flag-tagged MST1-KD in total cell
lysates were detected by Western blotting with
anti-Flag antibody. 
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bFGF Prevents Fas-mediated Apoptosis by Activating 
the Ras/MAPK Pathway
 
To investigate whether the activation of MAPK is in-
volved in the inhibition of Fas-mediated apoptosis by
bFGF, FH2 cells were transfected with an expression vec-
tor of K-RasN17, MKP-1, or 
 
D
 
p85, and then treated with
bFGF followed by the stimulation with anti-Fas mAb. Fig.
7 A shows that K-RasN17 and MKP-1 prevented the pro-
tective effect of bFGF against Fas-mediated apoptosis, al-
though 
 
D
 
p85 did not have any inhibitory effect on the ac-
tivity of bFGF. These results indicate that bFGF inhibits
Fas-mediated apoptosis in FH2 cells through activation of
MAPK.
We analyzed expression levels of endogenous and stably
expressed exogenous Fas on Balb3T3 cells and FH2 cells,
respectively, before and after the treatment with bFGF.
bFGF treatment did not downregulate expression levels
of Fas on either Balb3T3 cells (Fig. 7 B) or FH2 cells (data
not shown). These results show that the protective effect
of bFGF on Fas-mediated apoptosis is mediated by the
Ras/MAPK pathway without downregulating Fas expres-
sion.
It was reported previously that c-FLIP, which can inhibit
Fas-induced apoptosis (Irmler et al., 1997), is upregulated
by MAPKK activation in lymphocytes (Yeh et al., 1998).
We analyzed c-FLIP expression in FH2 cells pretreated
with or without bFGF by Northern hybridization. How-
ever, we could not detect specific expression of c-FLIP
mRNA by Northern hybridization, which indicates that
the expression level of c-FLIP mRNA in FH2 cells treated
with or without bFGF is low. Then we carried out RT-
PCR with c-FLIP–specific primers and detected the ex-
pression of c-FLIP mRNA (Fig. 7 C). The PCR product of
c-FLIP from the bFGF-treated cells was detected about
one cycle earlier than that from the nontreated cells. How-
ever, the PCR product of control EF1
 
a
 
 was observed
seven cycles earlier than c-FLIP (Fig. 7 C). These data sug-
gest that c-FLIP expression was upregulated by the bFGF
treatment about twice, but the expression level of c-FLIP
was low.
Figure 4. Activation of Raf/MAPK inhibits Fas-mediated apop-
tosis. (A) FH2 cells were transfected with an expression vector of
constitutively active mutants of Ras (K-RasV12), Raf (Raf-
CAAX), or MAPKK (SDSE-MAPKK), together with or without
that of MKP-1; or transfected with an expression vector of active
Akt or K-RasV12 together with that of HA-Dp85. Cells were
stimulated with 200 ng/ml agonistic anti-Fas mAb RK-8 and then
cell viability was determined. (B) Activation of caspase-3 was de-
termined as described in Materials and Methods. Nonspecific ex-
tra band was observed except for intact and cleaved MST1-KD.
(C) Transient expression of Myc–MKP-1 in total lysates of the
transfected cells was confirmed by Western blotting with anti-
Myc antibody. (D) Phosphorylation of Akt was detected by an
antibody against phospho-Akt in total lysates from the cells
transfected with an expression vector of Flag-Akt and K-RasV12
together with or without that of HA-Dp85. Upper and lower
bands indicate phosphorylated Flag-Akt and phosphorylated en-
dogenous Akt, respectively. Transient expression of HA-Dp85
and Flag-Akt in total lysates of transfected cells was detected by
anti-HA antibody and anti-Flag antibody, respectively. (E) Tran-
sient expression of active Akt (HA-myrD[4-129] Akt) in total cell
lysates was detected by anti-Akt antibody. 
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Discussion
 
We report here that transient expression of oncogenic
K-Ras inhibits Fas-mediated apoptosis in Fas-transgenic
Balb3T3 cells through the activation of the Ras/MAPK
pathway. Although the cells transfected with K-RasV12
were strongly resistant to the stimulation of Fas, pro-
longed stimulation 
 
.
 
8 h caused apoptosis in some of these
cells (Fig. 2 I). We observed that most of the surviving
cells transfected with K-RasV12, even after the prolonged
stimulation of Fas, show developed filamentous structures
in the cytoplasm, which may indicate strong expression of
transfected K-RasV12 (Fig. 2, I and J). These results sug-
gest that strong expression of oncogenic K-Ras can com-
pletely prevent untransformed cells from undergoing Fas-
mediated apoptosis, and explain how tumor cells escape
from immune surveillance by cytotoxic T cells during the
multistep progression of oncogenesis, because cytotoxic T
cells utilize Fas–Fas ligand system to kill tumor cells (Rou-
vier et al., 1993; Suda et al., 1993; Kojima et al., 1994).
Among partial loss-of-function mutants of Ras, RasS35
and RasG37 were reported to activate only Raf and Ral-
GDS, respectively. Both K-RasS35 and K-RasG37 par-
tially protected FH2 cells from Fas-mediated apoptosis
(Fig. 3 B). However, dominant-inhibitory RalN28 could
not cancel Ras-dependent protection against Fas-medi-
ated apoptosis (data not shown). Not only dominant-
inhibitory Ral but also dominant-inhibitory PI-3 kinase
subunit 
 
D
 
p85, which inhibited Ras-dependent activation of
PI-3 kinase (Fig. 4 D), could not disrupt the protective ac-
tivity of K-Ras against Fas-mediated apoptosis (Fig. 4 A).
In contrast, MKP-1, a phosphatase specific for activated
classical MAPK, could cancel the protective activity of
Figure 5. Flow cytometric analysis of Fas-expression on FH2 and
parental Balb3T3 cells transiently expressing K-RasV12, Raf-
CAAX, SDSE-MAPKK, or active Akt. (A) FH2 cells were stained
with PE-conjugated control hamster IgG (dotted line) or anti-Fas
mAb Jo-2 (solid line) and analyzed by flow cytometry. (B and C)
FH2 cells (B) and Balb3T3 cells (C) were transfected with an
empty vector (Control) or an expression vector of K-RasV12, Raf-
CAAX, SDSE-MAPKK, or active Akt together with pCMX-GFP.
After 48 h cultivation, cells were stained with PE-conjugated con-
trol hamster IgG (Non-stain) or PE-conjugated Jo-2, and analyzed
by two-dimensional flow cytometry. 
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K-RasV12, Raf-CAAX, and SDSE-MAPKK (Fig. 4 A).
Thus, activation of MAPK is essential for K-Ras–depen-
dent protection against Fas-mediated apoptosis in FH2
cells. However, the results indicating that the protective
activity of Raf-CAAX and SDSE-MAPKK was slightly
lower than that of K-RasV12 (Fig. 4, A and B) suggest that
another signaling pathway activated by K-Ras may con-
tribute to Ras-dependent protection against Fas-mediated
apoptosis.
We transfected K-RasV12 or K-RasN17 into other Fas-
transgenic cells prepared from tumor cell lines such as
HeLa and KB cells. Interestingly, Fas-mediated apoptosis
in these cells was neither inhibited by transient expression
of K-RasV12 nor enhanced by transient expression of
K-RasN17 or MKP-1 (data not shown). These cells were
relatively resistant to the stimulation with agonistic anti-
Fas mAb compared with FH2 cells. These results imply
that the protective activity of Ras/Raf/MAPK is specifi-
cally observed in untransformed cells or the cells more
sensitive to the stimulation of Fas than usual transformed
cell lines such as HeLa and KB cells.
We showed here that bFGF treatment desensitized fi-
broblasts to the stimulation of Fas through activation of
the Ras/MAPK pathway, because K-RasN17 and MKP-1
canceled the protective effect of bFGF (Fig. 7 A). How-
ever, the protective effect of bFGF was not sustained for a
long time (Fig. 6 A), and caspase-3 was gradually activated
after a 3-h stimulation of Fas (Fig. 6 D). These results indi-
cate that bFGF can exert its protective ability through the
Ras/MAPK pathway, but the activation of endogenous
Ras by bFGF may not be sufficient to protect cells against
continuous stimulation of Fas. We suppose that a more
sustained activation of the Ras/MAPK pathway, such as
by high expression of oncogenic K-RasV12 (Fig. 2, I and
J), is necessary for complete protection of cells against
Fas-mediated apoptosis.
The protective ability of bFGF against Fas-mediated
apoptosis was different from that of EGF (Fig. 6 A). Mar-
shall (1995) reviewed that stimulation of pheochromocy-
toma cell line PC12 with EGF leads to proliferation,
whereas stimulation with FGF or NGF leads to outgrowth
of neurites and eventual cessation of cell division. For the
difference of cellular responses of PC12 cells, the duration
of MAPK activation is claimed to be critical. In our exper-
iments, both bFGF and EGF could activate MAPK (Fig. 6
B), but only bFGF inhibited Fas-mediated apoptosis in fi-
broblasts (Fig. 6 A). The protective effect of bFGF may
also result from prolonged activation of MAPK, because
Figure 6. Pretreatment with
bFGF inhibits Fas-mediated
apoptosis. (A) FH2 cells were
pretreated with 100 ng/ml
EGF, 100 ng/ml IGF or 10 ng/
ml bFGF for 16 h, and then
stimulated with 200 ng/ml ago-
nistic anti-Fas mAb RK-8 for
the indicated times. Cell via-
bility was measured by amido
black staining assay (see Ma-
terials and Methods). (B) Ac-
tivation of MAPK in FH2
cells treated with EGF, IGF,
or bFGF was detected by
Western blotting with anti–
phospho-MAPK antibody.
Expression level of MAPK
was confirmed by Western
blotting with anti-MAPK antibody. (C and D) FH2 cells were pretreated with or without 10 ng/ml bFGF for 16 h and stimulated with
anti-Fas mAb RK-8 for the indicated times. Activation of caspases in cell lysate was measured using the fluorescent substrate IETD-
MCA and DEVD-MCA for caspase-8/6 (C) and caspase-3/7 (D), respectively. 
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we observed a more sustained activation of MAPK in FH2
cells treated with bFGF than with EGF (Fig. 6 B). By us-
ing the DNA chip technique, Fambrough et al. (1999) re-
ported that the stimulation of fibroblasts with PDGF or
FGF induces the expression of a set of genes designated as
immediate early genes (IEGs), and EGF induces expres-
sion of only a subset of IEGs. We suppose that the differ-
ence of the protective effect against Fas-mediated apopto-
sis between bFGF and EGF might be explained by the
difference in the set of IEGs induced by bFGF and EGF.
It was shown that oncogenic H-Ras downregulates the
expression of endogenous Fas in fibroblast and epithelial
cells through the activation of PI-3 kinase (Peli et al.,
1999). We analyzed the expression of Fas on FH2 cells
after the transfection with K-RasV12, Raf-CAAX, or
SDSE-MAPKK, or the treatment with bFGF. The results
did not show the downregulation of the expression level of
Fas enforced by 
 
b
 
-actin promoter in FH2 cells (Fig. 5 B;
data not shown). Thus, the activation of the Ras/MAPK
pathway was shown to be able to inhibit Fas-mediated
apoptosis even when the expression of Fas was not down-
regulated. In addition, not only transient expression of
K-RasV12, Raf-CAAX, SDSE-MAPKK, or active Akt,
but also pretreatment with bFGF did not downregulate
the expression of endogenous Fas in parental Balb3T3
cells (Fig. 5 C and Fig. 7 B). Our results indicate that acti-
vation of the Ras/MAPK pathway can confer cellular re-
sistance to Fas-mediated apoptosis without affecting the
expression of Fas when cells are treated with bFGF. The
different observations by others and us (Fenton et al., 1998;
Gibson et al., 1999; Peli et al., 1999) might arise from differ-
ent cells and/or different gene-expression system. In addi-
tion, we used K-Ras, whereas the others used H-Ras. A
difference of Ras might contribute to the distinct data, be-
cause functional differences were reported among Ras ho-
mologues (Voice et al., 1999).
In bFGF-treated FH2 cells, we detected about twofold
upregulation of c-FLIP transcript by RT-PCR when com-
pared with that in control FH2 cells (Fig. 7 C). However,
we could not detect c-FLIP mRNA in FH2 cells treated or
untreated with bFGF by Northern hybridization under the
condition where mRNA of caspase-8 and EF1
 
a
 
 were de-
tected (data not shown). We suppose that bFGF-induced
upregulation of c-FLIP mRNA is not sufficient to protect
FH2 cells from Fas-mediated apoptosis, because the quan-
tity of c-FLIP mRNA is much lower than that of caspase-8
mRNA in FH2 cells.
Here we clarified that the Ras/MAPK pathway pre-
vents Fas-mediated apoptosis in untransformed fibro-
blasts, which may contribute to oncogenesis. However, the
protective mechanism of the Ras/MAPK pathway remains
to be elucidated and must be clarified in the future.
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